Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: A method of coating spherical particles of a beta blocker compound which is based on (a) determining the surface area of a weighed sample of said spherical particles; (b) determining the weight of coating material per surface area unit of spherical particles that will provide a desired release profile for said beta-blocker; (c) determining the surface area of a subsequent batch of spherical particles containing the same beta; (d) coating the subsequent batch of spherical particles with the coating applied in step (b) to provide a coating having substantially the same weight of coating material per surface area unit of spherical particles as determined in step (b).

Abstract: The invention relates to a process for producing medicaments which comprise HMG CoA reductase inhibitors in the form of their salts, characterized in that the corresponding precursors of the actual active compounds are converted with bases, which contain alkali metal or alkaline earth metal ions, in a solvent, into the active compound, and the resulting active compound-containing solution is processed into the desired administration form.

Abstract: The invention relates to a process for producing medicaments which comprise HMG CoA reductase inhibitors in the form of their salts, characterized in that the corresponding precursors of the actual active compounds are converted with bases, which contain alkali metal or alkaline earth metal ions, in a solvent, into the active compound, and the resulting active compound-containing solution is processed into the desired administration form.

Abstract: The invention relates to flavor-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments.The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Abstract: The invention relates to flavour-masked pharmaceutical compositions for oral administration, their preparation and their use as medicaments.The new pharmaceutical preparations according to the invention make it possible to administer pharmaceutical active substances having very unpleasant organoleptic properties such as, for example, very bad taste, even in liquid form.

Abstract: Ciprofloxacin and related gyrase inhibitors are tolerated well if administered intramuscularly in the form of an aqueous suspension of the betaine form having an approximate neutral pH value or in the form of an oily suspension of the betaine or salts thereof. Oily suspensions which contain the active material in water-soluble form, eventually in form of the hydrochlorides, lactates, mesilates, methanesulfonates and other salts, are capable of releasing the active compound very rapidly, particularly when the wettability of the oily carrier medium is increased by addition of interfacially surface active materials.